الفهرس 
CHRONIC NONBACTERIAL PROSTATITISOnly 14 pages are availabe for public view
 |  | from | 129 |  |  |
| | | from | 129 | | |
Abstract
Background: Sensory receptors, for example transient receptor potential vanilloid 1, as well as sensory neurotransmitters, like substance p, calcitonin gene related peptide, & nerve growth factor, are responsible for providing the prostate with complete innervation. This may be a significant factor in the manifestation of symptoms associated with category III chronic prostatitis.
Aim and objectives: In order to assess the overall impact of the Botulinum toxin, type A in the treatment of category III chronic prostatitis compared to sham.
Subjects & Methods: this prospective randomized controlled trial (RCT) was conducted from April 2021 to august 2023. Ethical committee approval was taken and informed consent from each patient.
Result: There was statically significant improvment in total score of NIHCPSI in BONT-A group compared to saline group at all intervals of follow up. We found statically significant improvement in total NIHCPSI score follow up at 1 month (42%) ,3 months (78%) and 6 months (85%) ,pain subscale score follow up at 1 month (30%), 3 months (50%) and 6 months (76%) , quality of life score (QoL) at 1month (27%) ,3 months (43%) and 6 months (76%) and urinary symptoms score at 1 month(21%), 3 months (37%) and 6 months (67%) in BONT-A injection compared to saline injection . Small number of patients in saline group had improvement in total NIHCPSI score. Mild dysuria and hematuria were the only two postoperative complications encountered in both groups.
Conclusion: from the findings of this research, it can be concluded that the transurethral intraprostatic injection of BONT-A is a potential technique in the treatment of CP/CPPS that is resistant to medical treatment. When it comes to treating LUTS, lowering pain, along with improving quality of life, it might be useful.